Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy

Archives of Internal Medicine

Volumn 160, Issue 22, 2000, Pages 3431-3436

  Douketis, James D ^a,b   Foster, Gary A ^a,c   Crowther, Mark A ^a,b   Prins, Martin H ^d   Ginsberg, Jeffrey S ^b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN DERIVATIVE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034639245     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.22.3431     Document Type: Article

References (43)

1. Antithrombotic therapy for venous thromboembolic disease
2. Hemorrhagic complications of anticoagulant treatment
3. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy
4. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy
5. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
6. Risk factors for bleeding during treatment of acute venous thromboembolism
7. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
8. Major bleeding after hospitalization for deep-vein thrombosis
9. The long-term clinical course of acute deep vein thrombosis
10. The risk of fatal pulmonary embolism in patients with treated venous thromboembolism
11. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home
12. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis
13. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low-molecular-weight heparin
14. Assessment of outpatient treatment of deep vein thrombosis with low-molecular-weight heparin
15. Home treatment of deep vein thrombosis: A two-year experience at a single institution
16. Deep vein thrombosis: Longitudinal study with duplex US
17. Massive pulmonary embolism
18. Need for long-term anticoagulant treatment of symptomatic calf-vein thrombosis
19. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism
20. Long-term outcomes of deep-vein thrombosis
21. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
22. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
23. Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
24. Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism
25. Recurrent pulmonary embolism: A prospective study
26. Recurrent pulmonary embolism in patients treated because of acute venous thromboembolism: A prospective study
27. Criteria for outpatient management of proximal lower extremity deep vein thrombosis
28. Outpatient treatment of deep vein thrombosis: Translating clinical trials into practice
29. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
30. A standard heparin nomogram for the management of heparin therapy
31. A simple approach for detection of recurrent proximal vein thrombosis
32. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis
33. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan
34. Validation of a new criteria for the evaluation of bleeding during antithrombotic therapy
35. Efficacy and safety of oral anticoagulant therapy in patients with cancer
36. The prethrombotic state in cancer
37. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor
38. The duration of anticoagulant therapy after a second episode of venous thromboembolism
39. A comparison of three months of anticoagulant therapy with extended anticoagulation for a first episode of idiopathic venous thromboembolism
40. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis
41. Mortality in patients treated for pulmonary embolism
42. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
43. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy